Asimtufii: Withdrawal of the marketing authorisation application
aripiprazole
Table of contents
Overview
Otsuka Pharmaceutical Netherlands B.V. withdrew its application for a marketing authorisation of Asimtufii for the maintenance treatment of schizophrenia.
The company withdrew the application on 2 May 2023.
Key facts
Name |
Asimtufii |
Product number |
EMEA/H/C/005929 |
International non-proprietary name (INN) or common name |
|
Active substance |
|
Date of withdrawal |
02/05/2023 |
Company making the application | |
Withdrawal type |
Initial authorisation |
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').